Antigen-induced degranulation of mast cells plays a pivotal role in allergic and inflammatory responses. Recently, ceramide kinase (CERK) and its phosphorylated product ceramide 1-phosphate (C1P) have emerged as important players in mast cell degranulation. Here, we describe the synthesis of a novel F-12509A olefin isomer, K1, as an effective CERK inhibitor. In vitro kinase assays demonstrated that K1 effectively inhibits CERK without inhibiting sphingosine kinase and diacylglycerol kinase. Treating RBL-2H3 cells with K1 reduced cellular C1P levels to 40% yet had no effect on cell growth. Furthermore, treatment with K1 significantly suppressed both calcium ionophore-and IgE/antigen-induced degranulation, indicating that K1 interferes with signals that happen downstream of Ca 2+ mobilization. Finally, we show that K1 affects neither IgE/antigen-induced global tyrosine phosphorylation nor subsequent Ca 2+ elevation, suggesting a specificity for CERK-mediated signals. Our novel CERK inhibitor provides a useful tool for studying the biological functions of CERK and C1P. Moreover, to our knowledge, this is the first report demonstrating that inhibition of CERK suppresses IgE/antigen-induced mast cell degranulation. This finding suggests that CERK inhibitors might be a potential therapeutic tool in the treatment of allergic diseases.
Introduction
Antigen-induced aggregation of IgE receptor (FcεRI) in mast cells plays a pivotal role in allergic and inflammatory responses. Aggregation of this receptor prompts the recruitment and activation of cytosolic tyrosine kinases and phospholipases (1, 2) . These cellular events culminate in the exocytosis of granular content and subsequent allergic inflammation, such as that associated with asthma and anaphylaxis. Therefore, regulation of mast cell degranulation is a potential target for anti-allergic therapeutics.
3
The breakdown of sphingomyelin (SM) produces bioactive sphingolipid metabolites, including ceramide (CER), sphingosine (SPH), and sphingosine 1-phosphate (S1P). These sphingolipid metabolites play important roles in the regulation of cell proliferation, survival and apoptosis (3) (4) (5) . In particular, S1P has been implicated as a key factor in modulating mast cells (6) , and ceramide 1-phosphate (C1P), which is formed via the phosphorylation of CER by ceramide kinase (CERK), is emerging as an important mediator in mast cell degranulation (7, 8) . Both CERK and C1P have also been implicated in the regulation of neurotransmitter secretion, theoretically by increasing the fusibility of the vesicle membranes (9) , and C1P promotes phagolysosome formation and liposome fusion (10, 11) . These studies have identified C1P as a potent mediator for membrane fusion. C1P
induces cellular arachidonic acid release in A549 lung adenocarcinoma cells via activation of phospholipase A 2 (12) .
Human CERK was recently cloned based on its sequence homology to sphingosine kinase type 1 (SPHK1) (13) . CERK has an N-terminal plecstrin homology (PH) domain and a C-terminal Ca 2+ /calmodulin binding domain, and is activated by Ca 2+ (9) . Furthermore, the Ca 2+ /calmodulin binding domain is essential for the Ca 2+ -induced activation (14) . Such an increase in CERK activity, attributable to elevations in intracellular Ca 2+ levels, has been observed in rat basophilic leukemia cells following IgE/antigen treatment (7) . Moreover, both the calcium-induced CERK activation and the formation of C1P were found to be necessary steps in calcium ionophore-induced mast cell degranulation (7) .
Some sphingosine kinase inhibitors are known to modestly inhibit CERK at high concentrations in vitro (13) . However, to date, no specific and effective CERK inhibitor has been reported. Although C2-ceramide has been used to inhibit CERK activity (7) , it is also known to inhibit protein kinase C and IgE/antigen-induced phospholipase D (PLD) activation (15) (16) (17) . Furthermore, C2-ceramide is unsuitable as a therapeutic tool for allergic diseases, because of its high cytotoxicity (18) .
In our search of novel CERK inhibitors, we have developed analogs of F-12509A, a 3 4 previously reported SPHK inhibitor (19) . We have identified an olefin isomer of F-12509A that effectively and specifically inhibits CERK activity. Furthermore, this new CERK inhibitor suppresses RBL-2H3 mast cell degranulation, suggesting that this and other CERK inhibitors could be a potent therapeutic tool for allergic diseases.
Materials and methods

1. Synthesis and characterization of F-12509A and its analogs (Scheme 1, 2)
Alcohol 3
To a solution of acetonide 3 (1.388 g, 6.244 mmol) in tetrahydrofuran (30 mL) was added dropwise n-butyl lithium ( 
Xanthate 9
To a solution of alcohol 8 (218 mg, 0.652 mmol) in tetrahydrofuran (3. 
Acetonide 10
To a solution of xanthate 9 in toluene (7.8 mL) was added tributyltin hydride (2.1 mL, 7.843 mmol) and 2,2'-azobisisobutyronitrile (13 mg, 0.078 mmol) at room temperature. After the mixture was stirred for 1.5 h under reflux conditions, the solution was cooled at room temperature.
The solvent was removed in vacuo, and the crude products were purified by column chromatography on silica gel (from 0% to 3% ethyl acetate in hexane) yielding the corresponding acetonide 10 (207 mg, 
Dihydroxyquinone 11
To 
Plasmid construction and cell culture
pcDNA3-FLAG epitope-tagged mCERK was prepared as described elsewhere (7), and pcDNA3-HA-tagged hSPHK1 and HA-tagged hSPHK2 were constructed as previously described (20) .
Human embryonic kidney (HEK) 293 cells and rat basophilic leukemia (RBL-2H3) cells were cultured as monolayers in Dulbecco's modified Eagle's medium and Eagle's minimum essential medium, respectively (both from Sigma, St Louis, MO, USA). Chinese hamster ovary (CHO-K1) cells 8 9 were cultured in Ham's F-12 medium (Sigma). Media were supplemented with 10% (v/v) fetal bovine serum (BioSource International, Camarillo, CA, USA), 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma), and all cells were cultured at 37 ºC in a humidified atmosphere of 5% carbon dioxide. Transfections were performed using LIPOFECTAMINE-PLUS (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Plasmids used in the transfections were prepared with a Quantum Prep Plasmid Miniprep Kit (BIO-RAD, Hercules, CA, USA).
3. In vitro ceramide kinase assay
The activity of CERK was assayed as described by Bajjalieh et al. (8) Bands were quantified using a Fujix Bio-Imaging Analyzer, BAS2500 (Fuji Photo Film, Tokyo, Japan).
4. In vitro sphingosine kinase assay
The kinase activity of SPHK was assayed as previously described (20) . Briefly, lysates from CHO-K1 cells transfected with pcDNA3-HA-hSPHK1 or pcDNA3-HA-hSPHK2 were prepared as described for the ceramide kinase assay, and samples (1 μg protein) from each lysate were incubated at 37 ºC for 30 min with 2 μCi . S1P bands were visualized and quantified using a Fujix Bio-Imaging Analyzer, BAS2500.
4. In vitro diacylglycerol kinase (DGK) assay
The kinase activity of DGK was assayed as CERK assay with some modifications. Briefly, and 75 μl of 1M KCl were added, and the mixture was vortexed vigorously and centrifuged at 12,000 X g for 2 min. After centrifugation, the upper phase was removed, and the liquid was evaporated.
[ 32 P]C1P was detected by HPTLC using the same method as described above.
7. Cytotoxicity assay
Cytotoxicity was evaluated by measuring the mitochondrial dehydrogenase enzymatic 
8. Degranulation assays
Rat basophilic leukemia (RBL-2H3) cells were cultured as described above, centrifuged, washed, then resuspended in Tyrode's buffer (25 mM PIPES (pH 7.2), 119 mM NaCl, 5 mM KCl, 0.4 mM MgSO 4 , 5.6 mM glucose, 1 mM CaCl 2 , and 0.1% bovine serum albumin (BSA, Sigma)). For Ca
2+
ionophore stimulation, cells (1 x 10 7 cell/ ml, 100 µl) were pre-incubated with the CERK inhibitor (K1) for 10 min at 37 °C, then incubated with A23187 (final concentration 1 µM, Sigma) for 40 min at 37 °C. For IgE/antigen stimulation, cells were incubated at room temperature for 30 min in 10 µg/ml 12 anti-DNP IgE (a kind gift from Dr. Yamashita (22)), washed, incubated with inhibitors for 10 min at 37 °C, then stimulated with 1 µg/ml DNP-BSA for 40 min at 37 °C. After the applicable stimulation, all cells were centrifuged at 14,000 X g for 5 min, and the β-hexosaminidase activity was measured in both the supernatant and cell pellet, as described previously (21).
9. Western blot analysis
IgE/antigen stimulation was performed as described above, then cells were lysed with lysis buffer (62. 
11. Statistical analysis
The significance of differences was determined by Student's t test. Values were considered significant at P < 0.05
Results
1. Synthesis of F-12509A analogs
We recently synthesized a novel sphingosine kinase inhibitor, F-12509A (Scheme 1; compound 8), which was isolated from microbial metabolites (23) . In the course of that study, we synthesized an olefin regioisomer of F-12509A by reacting dl-arbicanal (compound 2) (24), derived from dl-arbicanol (Compound 1) (24), with a lithium anion generated from acetonide (compound 3) (26) to produce the adduct (compound 4), with a 77% yield. This compound (compound 4) was transformed into the corresponding xanthate (compound 5), which was treated with tributyltin hydride (27) in the presence of 2,2'-azobisisobutyronitrile to produce compound 6 in an 87% yield. Removal of the bisacetonide was successfully accomplished by the modification procedure of Snider's method (28) . Compound 7 (K1) was treated with trimethylsilyl trifluoromethanesulfonate in the presence of 1,3-propanedithiol, followed by treatment with tetrabutylammonium fluoride to produce compound 7, whose double bond is at the end position, in a 64% yield. Natural F-12509A (compound 8) and its enantiomer were synthesized by a similar method.
Cyclohexane derivative 11 (K2) was synthesized according to the procedure used for the F-12509A olefin isomer 7 (Scheme 2). Reacting cyclohexanecarboxaldehyde with the anione derived from the acetonide 3 gave adduct 8 in a 93% yield. After the obtained compound 8 was transformed 13 14 into the corresponding xanthate 9, this group was reductively removed by a radical reaction to obtain compound 10 in quantity. Treatment of compound 10 with acid produced the desired product 11 in a 73% yield. We have named compounds 7 and 11, K1 and K2, respectively.
2. K1 inhibits CERK activity in vitro
To determine whether F-12509A analogs are inhibitors of CERK activity, we first examined their effects in vitro. Of the analogs tested, K1 most effectively inhibited the CERK activity (Fig.1A) .
Consistent with a previous report (13), F-12509A exhibited modest inhibitory effects on CERK activity at high concentrations. In contrast, K1 showed a much stronger inhibitory effect than either F-12509A or K2 did (Fig.1A) . Since F-12509A was initially reported as a novel SPHK inhibitor, we also examined the inhibitory effect of K1 on SPHK1 and SPHK2, but surprisingly, found almost no inhibitory effect. We next examined effects of K1 on human DGK. As a result, a well konwn DGK inhibitor, R59949, inhibited DGKγ activity to 55% even at 10 μM (data not shown), but K1 had almost no inhibitory effect on DGKγ activity (Supplementary Figure 1) . Together, these data suggest that K1 has a specific inhibitory effect for CERK activity (Fig.1B) .
K1 is membrane permeable and an effective CERK inhibitor in intact cells
To determine whether K1 can also inhibit CERK in intact cells, we examined the amount of orthophosphoric acid, and incubated in the absence or presence of K1. In treated cells, the amount of [ 32 P]C1P decreased over time to 40% compared untreated cells (Fig.2) , indicating that K1 is membrane permeable and effective in intact cells. Unexpectedly, 100 μM K1 was not significantly more effective than 50 μM K1, suggesting that 50 μM is sufficient for maximum inhibition. Therefore, we set 100 μM as the maximum concentration used for further experiments.
4. K1 has no cytotoxic effect on RBL-2H3 cells
C2-ceramide and the common SPHK inhibitor N,N-dimethylsphingosine are both highly cytotoxic, so we also examined the cytotoxicity of K1. RBL-2H3 cells were incubated with K1 for 24
hours, and the cell viability was analyzed by measuring the mitochondrial dehydrogenase activity.
Interestingly, even at 100 μM, K1 did not affect the growth of RBL-2H3 cells (Fig.3) . This result clearly demonstrates that K1has no cytotoxicity.
5. Suppression of mast cell degranulation by K1
In a previous study, we demonstrated that CERK is involved in calcium ionophore-induced mast cell degranulation. Here, we analyzed the effect of K1 on calcium ionophore-induced deregulation in RBL-2H3 cells by measuring the release of β-hexosaminidase. K1 inhibited the induced β-hexosaminidase release, in a dose dependent manner (Fig.4A ). Approximately 50%
inhibition was achieved at a concentration of 100 μM K1. Additionally, even at 100 μM, K1 did not affect baseline values of β-hexosaminidase release, suggesting that its inhibitory effect was limited to the calcium ionophore-induced release (Fig.4A) . In RBL-2H3 cells, calcium ionophore alone can induce mast cell degranulation, indicating that Ca 2+ elevation can mediate all the required steps (29) .
Similar downstream signaling leads to granule fusion and exocytosis in IgE/antigen-induced degranulation (7). Therefore, we next examined the effect of K1 on IgE/antigen-induced mast cell degranulation. IgE/antigen-induced degranulation was suppressed by K1, with similar dose dependency and suppression efficacy as those observed for the calcium ionophore-induced degranulation (Fig.4B) . Inhibition of the calcium ionophore-or IgE/antigen-induced degranulation by a CERK inhibitor provides further evidence that CERK mediates the downstream signaling of Ca 2+ .
6. K1 has no discernible effect on IgE/antigen-induced global tyrosine phosphorylation and
Ca
2+ elevation
To determine whether K1 intervenes in the initial steps of IgE/antigen-induced degranulation pathways, we examined its effect on the global tyrosine phosphorylation and Ca 2+ elevation triggered 15 by FcεRI cross-linking. Western blot analysis using an anti-phosphotyrosine antibody indicated that IgE/antigen induced-tyrosine phosphorylation was not affected by 100 μM K1 treatment (Fig.5A ). This result rules out the possibility that K1 treatment suppresses mast cell degranulation by inhibiting the tyrosine phosphorylation of signaling molecules. We next examined IgE/antigen-induced Ca 2+ mobilization using Fura-2/AM. There was no significant difference between the K1-treated cells and control cells (vehicle-treated) (Fig.5B) , indicating that K1 treatment does not affect the signaling pathways from FcεRI to Ca 2+ mobilization. In conclusion, the absence of any detectable effect by K1 on tyrosine phosphorylation or Ca 2+ mobilization suggests that has no side effect on the initial steps in
FcεRI signaling, and that it specifically inhibits the downstream signaling following IgE/antigen-induced Ca 2+ mobilization.
Discussion
We report here on the synthesis of a CERK inhibitor capable of preventing mast cell degranulation. Although being an olefin isomer of the SPHK inhibitor F12509A, K1 specifically inhibited CERK in vitro without inhibiting SPHKs and DGKγ (Fig.1B and Supplementary Figure 1) .
Furthermore, since SPHK inhibition prevents IgE/antigen-induced Ca 2+ mobilization (30) (31) (32) , the absence of similar inhibition by K1 (Fig.5B ) rules out the possibility that K1 suppresses mast cell degranulation by inhibiting SPHK activity. Although both SPHK and CERK are known to be involved in mast cell degranulation, these results suggest these kinases mediate distinct pathways in FcεRI signaling.
Treatment of RBL-2H3 cells with 100 μM K1 reduced C1P levels to 40% (Fig.2) , and K1 suppressed mast cell degranulation to a similar extent (Fig.4 A, B) . Collectively, these results imply a relationship between intracellular C1P levels and degranulation. Relative to its effects in vitro (Fig.2) , K1 exhibited less inhibition in living cells (Fig.2) . This may be due to the low membrane permeability of K1. Future studies to modify the K1 structure to design improved CERK inhibitors with greater 16 efficacy in living cells will be of great interest.
Previous studies have used C2-ceramide to inhibit CERK activity. However, C2-ceramide is highly cytotoxic and exhibits broad specificity (14) (15) (16) (17) . In contrast, K1 has advantages not only in its selectivity but also in being nontoxic (Fig.3) , making K1 a more useful and accurate tool than currently available compounds in identifying roles for CERK.
Several protein-tyrosine kinase (PTK) inhibitors have been reported to inhibit mast cell activation. For instance, ER-27319 and terreic acid inhibit IgE/antigen-induced mast cell activation by specifically inhibiting Syk and Btk, respectively (33, 34) . However, PTK inhibitors target molecules involved in early signaling events following antigen stimulation, and some are cytotoxic because of the multiple roles of PTKs in cellular signaling. Thus, targeting not only the molecules in the signaling pathways initiated by FcεRI cross-linking but also molecules required for granule fusion and exocytosis, provides a rational strategy for anti-allergy therapeutics (35) . Thus, inhibition of CERK may be a novel approach to inhibiting mast cell degranulation by regulating granule fusion and exocytosis.
Accumulating evidence implicates CERK as a novel regulator of granule to plasma membrane fusion 
